Harbinger Health Showcases Two-Tiered MCED Test With Strong Specificity And Per-Cancer Accuracy

Novel Methylation-Based Approach Targets Hard-To-Screen Cancers In High-Risk Populations

 
• By Shubham Singh
  
Harbinger’s MCED test is built on proprietary methylation profiling of circulating tumor DNA (ctDNA) from blood samples.

More from Diagnostics

More from Medtech Insight